RUNX3 and cancer: In gastric cancer, RUNX3 participates in TGF-β1-dependent cell growth suppression by binding to promoter p21 and inducing expression of CDKN1A (cyclin-dependent kinase inhibitor) that leads to inhibition of cancer cell proliferation [50].